Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1843 1
1946 1
1947 3
1948 6
1949 6
1950 2
1951 3
1952 2
1953 1
1954 2
1955 3
1956 1
1957 4
1958 2
1959 2
1960 4
1961 1
1962 2
1963 2
1964 5
1965 5
1966 4
1967 2
1968 2
1969 3
1970 7
1971 5
1972 6
1973 14
1974 7
1975 4
1976 12
1977 3
1978 9
1979 6
1980 4
1981 2
1982 11
1983 4
1984 4
1985 6
1986 2
1987 5
1988 5
1989 8
1990 4
1991 5
1992 4
1993 5
1994 4
1995 3
1996 6
1997 2
1998 2
2000 4
2001 8
2002 5
2003 5
2004 2
2005 4
2006 4
2007 5
2008 2
2009 4
2010 6
2011 6
2012 6
2013 9
2014 5
2015 3
2016 5
2017 2
2018 5
2019 11
2020 7
2021 10
2022 9
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Results by year

Filters applied: . Clear all
Page 1
Klebsiella pneumoniae liver abscess: a new invasive syndrome.
Siu LK, Yeh KM, Lin JC, Fung CP, Chang FY. Siu LK, et al. Lancet Infect Dis. 2012 Nov;12(11):881-7. doi: 10.1016/S1473-3099(12)70205-0. Lancet Infect Dis. 2012. PMID: 23099082 Review.
During the past two decades, however, a distinct invasive syndrome that causes liver abscesses has been increasingly reported in Asia, and this syndrome is emerging as a global disease. ...Diabetes mellitus and two specific capsular types in the bacterium predispose a pati …
During the past two decades, however, a distinct invasive syndrome that causes liver abscesses has been increasingly reported in Asia …
Complicated pneumonia in children.
de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. de Benedictis FM, et al. Lancet. 2020 Sep 12;396(10253):786-798. doi: 10.1016/S0140-6736(20)31550-6. Lancet. 2020. PMID: 32919518 Review.
Complicated community-acquired pneumonia in a previously well child is a severe illness characterised by combinations of local complications (eg, parapneumonic effusion, empyema, necrotising pneumonia, and lung abscess) and systemic complications (eg, bacteraemia, metastat …
Complicated community-acquired pneumonia in a previously well child is a severe illness characterised by combinations of local complications …
Monkeypox.
Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. Mitjà O, et al. Lancet. 2023 Jan 7;401(10370):60-74. doi: 10.1016/S0140-6736(22)02075-X. Epub 2022 Nov 17. Lancet. 2023. PMID: 36403582 Free PMC article. Review.
Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1 …
Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and in …
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
The primary endpoint was the proportion of patients with a hidradenitis suppurativa clinical response, defined as a decrease in abscess and inflammatory nodule count by 50% or more with no increase in the number of abscesses or in the number of draining fistulae com …
The primary endpoint was the proportion of patients with a hidradenitis suppurativa clinical response, defined as a decrease in abscess …
Amoebiasis.
Stanley SL Jr. Stanley SL Jr. Lancet. 2003 Mar 22;361(9362):1025-34. doi: 10.1016/S0140-6736(03)12830-9. Lancet. 2003. PMID: 12660071 Review.
Amoebic liver abscesses grow inexorably and, at one time, were almost always fatal, but now even large abscesses can be cured by one dose of antibiotic. ...New models of disease have linked E histolytica induction of intestinal inflammation and hepatocyte programmed …
Amoebic liver abscesses grow inexorably and, at one time, were almost always fatal, but now even large abscesses can be cured …
Lemierre's syndrome due to Fusobacterium necrophorum.
Kuppalli K, Livorsi D, Talati NJ, Osborn M. Kuppalli K, et al. Lancet Infect Dis. 2012 Oct;12(10):808-15. doi: 10.1016/S1473-3099(12)70089-0. Epub 2012 May 25. Lancet Infect Dis. 2012. PMID: 22633566 Review.
We present a case of a patient with Lemierre's syndrome caused by Fusobacterium necrophorum who developed a right frontal lobe brain abscess. We summarise the epidemiology, microbiology, pathogenesis, clinical presentation, diagnosis, complications, therapy, and outcomes o …
We present a case of a patient with Lemierre's syndrome caused by Fusobacterium necrophorum who developed a right frontal lobe brain absc …
Clinical features and management of human monkeypox: a retrospective observational study in the UK.
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM; NHS England High Consequence Infectious Diseases (Airborne) Network. Adler H, et al. Lancet Infect Dis. 2022 Aug;22(8):1153-1162. doi: 10.1016/S1473-3099(22)00228-6. Epub 2022 May 24. Lancet Infect Dis. 2022. PMID: 35623380 Free PMC article.
Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess. Five patients spent more than 3 weeks (range 22-39 days) in isol …
Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and …
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
There were four serious adverse events in three patients considered treatment-related (pneumonia [n=1] and gastroenteritis [n=1] in the placebo group; appendicitis plus tubo-ovarian abscess in the same patient in the ianalumab 50 mg group). INTERPRETATION: The study met it …
There were four serious adverse events in three patients considered treatment-related (pneumonia [n=1] and gastroenteritis [n=1] in the plac …
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
Five deaths were deemed treatment-related: two in the nivolumab group (one each of interstitial lung disease and pneumonitis) and three in the chemotherapy group (one each of pneumonia, spinal cord abscess, and interstitial lung disease). INTERPRETATION: Nivolumab was asso …
Five deaths were deemed treatment-related: two in the nivolumab group (one each of interstitial lung disease and pneumonitis) and three in t …
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Patients with diseased terminal ileum longer than 40 cm or abdominal abscesses were excluded. The primary outcome was quality of life on the Inflammatory Bowel Disease Questionnaire (IBDQ) at 12 months. ...
Patients with diseased terminal ileum longer than 40 cm or abdominal abscesses were excluded. The primary outcome was quality of life …
363 results